Perspective of Cyclin-dependent kinase 9 (CDK9) as a Drug Target

0382222 - ÚEB 2013 RIV GB eng J - Článek v odborném periodiku
Kryštof, Vladimír - Baumli, S. - Fürst, R.
Perspective of Cyclin-dependent kinase 9 (CDK9) as a Drug Target.
Current Pharmaceutical Design. Roč. 18, č. 20 (2012), s. 2883-2890. ISSN 1381-6128. E-ISSN 1873-4286
Grant CEP: GA ČR GAP305/12/0783
Výzkumný záměr: CEZ:AV0Z50380511
Klíčová slova: Cancer * inflammation * kinase
Kód oboru RIV: ED - Fyziologie
Impakt faktor: 3.311, rok: 2012
http://www.benthamdirect.org/pages/article/1/3177374/perspective-of-cyclin-dependent-kinase-9-cdk9-as-a-drug-target.html

Deregulation of cyclin-dependent kinases (CDKs) has been associated with many cancer types and has evoked an interest in chemical inhibitors with possible therapeutic benefit. While most known inhibitors display broad selectivity towards multiple CDKs, recent work highlights CDK9 as the critical target responsible for the anticancer activity of clinically evaluated drugs. In this review, we discuss recent findings provided by structural biologists that may allow further development of highly specific inhibitors of CDK9 towards applications in cancer therapy. We also highlight the role of CDK9 in inflammatory processes and diseases.
Trvalý link: http://hdl.handle.net/11104/0212510